The systemic lupus erythematosus (SLE) treatment pipeline is experiencing unprecedented expansion, driven by increasing disease awareness, rising pre ...

Flare and persistently active disease are prevalent in a multinational cohort study of patients with systemic lupus erythematosus, with some having persistently active disease without flare.

Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...

GSK plc (LSE/NYSE: GSK) today announced the launch of the Linked by Lupus: Optimal Care Initiative to help support ...

New research by Swansea University and Cambridge University has revealed the causes and devastating impacts of delays—that ...

Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in ...

Called enpatoran, the agent targets the Toll-like receptor (TLR) species 7 and 8. Some 50%-60% of patients with systemic ...

One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

This article explores the complex roles of cytokine networks in the development and progression of autoimmune diseases.

CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...

SLE Disease Activity Index. Lupus 8(6), 462-465 (1999). Maddison PJ: Systemic lupus erythematosus in the ... Is chloroquine obsolete in treatment of rheumatic disease? Lancet 1(8112), 371-373 ...